1
Piening, Sigrid, Haaijer-Ruskamp, Flora M., de Graeff, Pieter A., Straus, Sabine M. J. M., Mol, Peter G. M.
Veröffentlicht in: Piening , S , Haaijer-Ruskamp , F M , de Graeff , P A , Straus , S M J M & Mol , P G M 2012 , ' Healthcare professionals' self-reported experiences and preferences related to direct healthcare professional communications : a survey conducted in the Netherlands ' , Drug Safety , vol. 35 , no. 11 , pp. 1061-1072 .;
2012
Veröffentlicht in: Piening , S , Haaijer-Ruskamp , F M , de Graeff , P A , Straus , S M J M & Mol , P G M 2012 , ' Healthcare professionals' self-reported experiences and preferences related to direct healthcare professional communications : a survey conducted in the Netherlands ' , Drug Safety , vol. 35 , no. 11 , pp. 1061-1072 .;
2012
2
Crijns, H.J., van Rein, N., Gispen-de Wied, C.C., Straus, S.M., de Jong-van den Berg, L.T.
Veröffentlicht in: Crijns , H J , van Rein , N , Gispen-de Wied , C C , Straus , S M & de Jong-van den Berg , L T 2012 , ' Prescriptive contraceptive use among isotretinoin users in the Netherlands in comparison with non-users : a drug utilisation study ' , Pharmacoepidemiology and Drug Safety , vol. 21 , no. 10 , pp. 1060-1066 . https://doi.org/10.1002/pds.3200;
2012
Veröffentlicht in: Crijns , H J , van Rein , N , Gispen-de Wied , C C , Straus , S M & de Jong-van den Berg , L T 2012 , ' Prescriptive contraceptive use among isotretinoin users in the Netherlands in comparison with non-users : a drug utilisation study ' , Pharmacoepidemiology and Drug Safety , vol. 21 , no. 10 , pp. 1060-1066 . https://doi.org/10.1002/pds.3200;
2012
3
Arnardottir, Arna H., Haaijer-Ruskamp, Flora M., Straus, Sabine M. J., Eichler, Hans-Georg, de Graeff, Pieter A., Mol, Peter G. M.
Veröffentlicht in: Arnardottir , A H , Haaijer-Ruskamp , F M , Straus , S M J , Eichler , H-G , de Graeff , P A & Mol , P G M 2011 , ' Additional safety risk to exceptionally approved drugs in Europe? ' , British Journal of Clinical Pharmacology , vol. 72 , no. 3 , pp. 490-499 . https://doi.org/10.1111/j.1365-2125.2011.03995.x;
2011
Veröffentlicht in: Arnardottir , A H , Haaijer-Ruskamp , F M , Straus , S M J , Eichler , H-G , de Graeff , P A & Mol , P G M 2011 , ' Additional safety risk to exceptionally approved drugs in Europe? ' , British Journal of Clinical Pharmacology , vol. 72 , no. 3 , pp. 490-499 . https://doi.org/10.1111/j.1365-2125.2011.03995.x;
2011
4
5
6